Physician profile
Mark R Rosenberg
NPI 1598869687
$843.98
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $224 · 2021: $19.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $337.68 | 2019 | |
| Amgen INC. | $249.50 | 2019-2020 | |
| Abbvie INC. | $86.01 | 2019 | |
| Astellas Pharma US INC | $55.19 | 2020 | |
| Lilly USA, LLC | $34.70 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.84 | 2020 | |
| Mayne Pharma Commercial LLC | $19.88 | 2019 | |
| Pfizer INC. | $19.50 | 2021 | |
| Leo Pharma INC. | $17.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.